Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 33 of 151

  1. CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    BEONE MEDICINES AUS PTY LTD

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  2. CD123 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  3. CD123 targeted CAR-NK cells

    Chongqing Precision Biotech Co., Ltd

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  4. CD19 CAR T-Cell(CAT19T2)

    Zhujiang Hospital

    B-cell Acute Lymphoblastic Leukemia

    phase 2 mab terminated

    1 trial

  5. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  6. CD19 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  7. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 mab active

    1 trial

  8. CD19 CAR-T cells and CD19 positive feeder T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

  9. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials

  10. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  11. CD19 and CD22 targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    B-ALL

    phase 2 mab active

    1 trial

  12. CD19 or CD20 CAR T cells briging HSCT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  13. CD19X CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-Cell Lymphoma (LBCL)

    phase 2 small molecule active

    1 trial

  14. CD22/CD19 CAR T and auto-HSCT "sandwich" strategy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Acute Lymphoblastic Leukemia

    phase 2 other active

    1 trial

  15. CD25 antibody combined glucocorticoid as first-line treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Graft Versus Host Disease

    phase 2 small molecule active

    1 trial

  16. CDC-NCHSTP-4448

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 2 small molecule completed

    1 trial

  17. CDFV890B12201

    Novartis Pharmaceuticals

    Knee Osteoarthritis

    phase 2 small molecule active

    1 trial

  18. CDZR123A02101

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  19. CDZR123A12107

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  20. CDZR123C12101

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  21. CE-326,597 100 mg QD

    Pfizer

    Weight Management

    phase 2 small molecule completed

    1 trial

  22. CE-Iohexol

    LIGAND PHARMACEUTICALS INC

    Contrast-induced Nephropathy

    phase 2 small molecule terminated

    1 trial

  23. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Solid Tumor

    phase 2 mab active

    1 trial

  24. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 2 mab active

    3 trials

  25. CEC-013/CEL

    Dr. Falk Pharma GmbH

    Celiac Disease

    phase 2 small molecule active

    1 trial

  26. CECI830A12101

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  27. CEMIPLIMAB

    Fondazione Telethon ETS

    surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma, Cutaneaous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  28. CEP-18770

    Teva Generics B.V

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  29. CEP-18770

    Teva Pharma GmbH

    Multiple Myeloma

    phase 2 small molecule terminated

    2 trials

  30. CEP-37247

    Teva Pharma GmbH

    Sciatica

    phase 2 small molecule completed

    1 trial

  31. CEP-701

    Teva Pharma GmbH

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  32. CEP-701

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  33. CEP-701 20mg

    Teva Pharma GmbH

    Psoriasis

    phase 2 small molecule completed

    1 trial

  34. CEP-701 60mg

    Teva Pharma GmbH

    Leukemia, Myeloid

    phase 2 small molecule completed

    1 trial

  35. CEP-9722

    Teva Pharma GmbH

    Solid Tumors

    phase 2 small molecule terminated

    1 trial

  36. CERC-002

    Avalo Therapeutics

    COVID-19 Pneumonia

    phase 2 small molecule completed

    1 trial

  37. CERC-301

    Avalo Therapeutics

    Major Depressive Disorder

    phase 2 small molecule completed

    2 trials

  38. CERC-501

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    1 trial

  39. CERE-110: Adeno-Associated Virus injection Surgery

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  40. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  41. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  42. CET/PT

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 other completed

    1 trial

  43. CETUXIMAB for ADCC, Colorectal Cancer

    Fondazione Telethon ETS

    ADCC, Colorectal Cancer

    phase 2 small molecule active

    1 trial

  44. CF 102

    Can-Fite BioPharma

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  45. CF101

    Can-Fite BioPharma

    Uveitis, Posterior

    phase 2 small molecule terminated

    1 trial

  46. CF101

    Can-Fite BioPharma

    Osteoarthritis of the Knee

    phase 2 small molecule terminated

    1 trial

  47. CF101

    Can-Fite BioPharma

    Ocular Hypertension

    phase 2 small molecule completed

    1 trial

  48. CF101

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 2 small molecule completed

    3 trials

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.